Oramed Pharmaceuticals

Historical price data

Oramed Pharmaceuticals is a clinical-stage biotech company with a mission to transform injectable therapies into oral medications, thereby improving patient compliance and quality of life. Its core achievement is the development of the POD™ (Protein Oral Delivery) technology platform, which is designed to protect and enhance the absorption of large molecules through the gastrointestinal tract. The company's strategy is centered on advancing its late-stage oral insulin candidate for Type 2 Diabetes and Non-Alcoholic Steatohepatitis (NASH), while exploring applications for other high-value peptides like GLP-1. Oramed has also demonstrated financial acumen through strategic transactions, generating significant non-dilutive returns for shareholders.

Proprietary POD™ (Protein Oral Delivery) technology platform designed to orally deliver large molecule drugs via enteric protection, protease inhibitors, and absorption enhancers.

Oramed is a leader in late-stage oral insulin but faces competition from alternative delivery methods (inhaled, patches) and, in the GLP-1 space, from dominant players like Novo Nordisk with an approved oral GLP-1. Its success hinges on demonstrating clear advantages over these established and emerging alternatives.